top of page

Comparing Genetic Approaches for Identifying Drug Targets: A Study Reveals Effective Methods

TAIPEI, TAIWAN, Jul 1, 2023- A team of researchers have conducted a comprehensive comparison of several genetic approaches to ascertain their effectiveness in identifying drug targets. The approaches under scrutiny included Genome-Wide Association Studies (GWAS), Quantitative Trait Loci (QTL) analyses, exome sequencing, and network diffusion analyses. The main objective was to establish which technique was most efficient in recognizing approved drug targets for a variety of diseases.

The study, which was carried out by researchers based in Switzerland and The Netherlands and published in Cell Genomics, aimed to assess these gene prioritization methods, each of which has demonstrated its effectiveness independently in pinpointing drug targets.

Although GWAS is widely recognized as the most beneficial method, other techniques such as mQTL datasets and whole-exome sequencing have also made significant contributions in the discovery of disease mechanisms and potential drug targets.

In order to undertake a fair comparison, the researchers utilized publicly accessible datasets and computed gene scores. They found that all the methods under review enriched drug targets among the prioritized genes. GWAS showed superiority over eQTL-GWAS and pQTL-GWAS in pinpointing drug targets, but the exome approach also proved valuable.

Moreover, the researchers employed network connectivity to identify potential drug target genes associated with disease genes. The use of network analysis enhanced target prioritization across the different methods.

Nevertheless, the study was not without its limitations, which included a bias in the network used for connectivity analysis and a lack of consideration for the directionality of therapeutic and genetic effects. The researchers noted that the results might be more indicative of the genetic approaches' ability to identify historically prioritized drug targets rather than truly novel disease genes.

About WASAI Technology Inc.

WASAI Technology's mission is to deliver acceleration technologies of High-Performance Data Analysis (HPDA) in future data centers for targeted vertical applications with massive volumes and high velocities of scientific data. To strengthen and advance scientific discovery and technological research via big data-intensive acceleration in high-performance computing, WASAI Technology aims to improve commercialization and commoditization of scientific and technological applications.



WASAI Tecnology Inc.

4F, No. 6, Zhiyuan 3rd Rd., Beitou Dist., Taipei 112025, Taiwan

bottom of page